arrow
M

Madlen Jentzsch

department for hematology
H指数:21
被引数:1,229

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Low muscle quality, but not muscle mass, in abdominal CT-scans associates with adverse outcomes in AML patients undergoing an allogeneic stem cell transplantation

腹部CT扫描显示肌肉质量低而非肌肉量与接受异基因干细胞移植的AML患者的不良预后相关

2026-08-130
OAAI
Clonal Hematopoiesis does not influence manufacturing of Chimeric Antigen Receptor (CAR) T-Cells

克隆性造血不影响嵌合抗原受体(CAR)T细胞的制备

2026-06-030
OAAI
Impact of Renal Impairment and Lymphodepletion Regimen on Outcomes after CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma

肾损伤和淋巴清除方案对复发/难治性多发性骨髓瘤CAR T细胞治疗预后的影响

2026-05-160
PRE
Body composition predicts poor outcomes and reveals immunometabolic dysfunction via single-cell profiling in anti-BCMA CAR T-treated myeloma

体成分通过单细胞分析预测抗BCMA CAR T治疗的骨髓瘤患者的预后不良并揭示免疫代谢功能障碍

2026-03-240
OAAI
MyCARdiac score: integrating cardiac imaging and biomarkers to predict outcomes in RRMM patients receiving cilta-cel

MyCARdiac评分:整合心脏成像和生物标志物以预测接受cilta-cel治疗的RRMM患者的结局

Leukemia
IF13.4
2026-02-170
OAAI
The sequence of 12 Gy total body irradiation and cyclophosphamide does not impact outcomes in AML patients receiving myeloablative allogeneic stem cell transplantation

12 Gy全身照射和环磷酰胺的顺序不会影响接受骨髓 ablative 异基因干细胞移植的AML患者的结局

2025-12-020
OAAI
Impact of cellular composition and T-cell senescence of mononuclear cell concentrates on the manufacturing process of chimeric antigen receptor (CAR) T-cells

单核细胞浓缩物中细胞组成和T细胞衰老对嵌合抗原受体(CAR)T细胞制备过程的影响

2025-07-290
OA
Gemtuzumab ozogamicin in first-line treatment of CBF-AML: insights from a retrospective multi-center analysis

吉姆单抗奥佐米星在CBF-AML一线治疗中的应用:一项回顾性多中心分析的见解

Leukemia
IF13.4
2025-07-210
OA
Prognostic implications of splenomegaly in BCMA-directed CAR T-Cell therapy for relapsed myeloma

脾肿大在BCMA靶向CAR T细胞疗法治疗复发多发性骨髓瘤中的预后意义

2025-07-160
OAAI
Induction chemotherapy with CPX-351 in acute myeloid leukemia: revisiting the role of early bone marrow assessment

CPX-351在急性髓系白血病中的诱导化疗:重新评估早期骨髓评估的作用

Leukemia
IF13.4
2025-07-030
OAAI
Impact of Evolving WHO and ICC Classifications on Prognosis and Outcomes in AML Patients Undergoing Allogeneic Stem Cell Transplantation

世界卫生组织(WHO)和欧洲血液和骨髓移植学会(EBMT)分类的演变对接受异基因造血干细胞移植的急性髓系白血病(AML)患者预后和结局的影响

2025-04-080
PRE
Azacitidine in combination with shortened venetoclax treatment cycles in patients with acute myeloid leukemia

阿扎胞苷联合维尼托克缩短治疗周期治疗急性髓系白血病

2024-10-250
OAAI
Hematopoietic cell transplantation for older acute myeloid leukemia patients in first complete remission: results of a randomized phase III study

首次完全缓解的老年急性髓性白血病患者的造血细胞移植: 一项随机III期研究的结果

2024-08-081
OAAI
Single-cell multiomic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma

复发性多发性骨髓瘤中针对BCMA的嵌合抗原受体T细胞的反应和抗性的单细胞多体解剖

2024-04-196
OA